DSM Pharmaceutical Products signed a nonexclusive license deal with Amgen, giving the company access to DSM’s proprietary XD® high cell density process patents.
“We are pleased to enter into this license agreement with Amgen, a global leader in biopharmaceutical drug development and manufacturing,” said Karen King, president of DSM Biologics.
“With typical XD titer improvement of 8–10X, a 500 L bioreactor can provide a DSM licensee with the same amount of drug substance as a 5000 L stainless steel bioreactor at an overall lower cost,” added Alexander Wessels, president and CEO of DSM Pharmaceutical Products.
Last October, DSM Pharmaceutical Products, the contract manufacturing arm of Royal DSM, entered into a contract manufacturing agreement with Australia-based Paranta Biosciences, covering the process development and cGMP manufacture Paranta’s lead recombinant human protein. That same month, DSM Pharmaceutical Products inked a collaboration agreement with the Almac Group in the field of biocatalysis to provide sustainable manufacturing services to the pharmaceutical industry.
